title: Targeted caval cytoreduction: solid foundations or shifting sands?
authors: Axel
authors: A
authors: Bex
authors: Noel
authors: N
authors: Clarke
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D058990:Molecular Targeted Therapy; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009392:Nephrectomy; D018579:Patient Selection; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D018570:Risk Assessment; D012307:Risk Factors; D000077210:Sunitinib; D017131:Thrombectomy; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects; D014682:Vena Cava, Inferior / Q000473:pathology* / Q000601:surgery; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000601:surgery
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000068258:Bevacizumab; D000077210:Sunitinib